Medicare AdvantageCoverageMedium impact
MA08.045m, Tocilizumab and Related Biosimilars for Intravenous Infusion and Subcutaneous Injection
Independence Blue Cross·MA · Rheumatology, Internal Medicine, Gastroenterology +2 more·Pharmacy
Effective date
Jul 1, 2025
We identified it
Jun 19, 2026
Summary
Policy MA08.045m establishes coverage and reimbursement criteria for Tocilizumab and related biosimilars administered intravenously or subcutaneously. This policy includes updated medical necessity criteria and coding requirements effective July 1, 2025. The billing team must review medical necessity documentation requirements and ensure proper coding alignment for all Tocilizumab claims.
Action Required
By June 30, 2025: Billing team must obtain and review the complete MA08.045m policy text to identify specific HCPCS codes (J-codes for Tocilizumab biosimilars) and any prior authorization requirements. Update billing system rules to enforce medical necessity criteria for all Tocilizumab infusions and injections. Providers must document clinical justification per policy requirements on all orders. Verify coding accuracy in billing software. Communicate updated requirements to clinical staff. Without proper documentation and coding alignment, claims will be denied.